Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast09: Trastuzumab Deruxtecan +/- Pertuzumab in First-line HER2-positive Metastatic Breast Cancer
NCT04784715Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in breast cancer, sponsored by AstraZeneca. Started Apr 2021; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04784715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784715.